pDONR223-MAGI1 Citations (2)
Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal
Articles Citing pDONR223-MAGI1
| Articles |
|---|
| Dynamic control of RSK complexes by phosphoswitch-based regulation. Gogl G, Biri-Kovacs B, Poti AL, Vadaszi H, Szeder B, Bodor A, Schlosser G, Acs A, Turiak L, Buday L, Alexa A, Nyitray L, Remenyi A. FEBS J. 2018 Jan;285(1):46-71. doi: 10.1111/febs.14311. Epub 2017 Nov 20. PubMed |
| MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis. Kantar D, Mur EB, Mancini M, Slaninova V, Salah YB, Costa L, Forest E, Lassus P, Geminard C, Boissiere-Michot F, Orsetti B, Theillet C, Colinge J, Benistant C, Maraver A, Heron-Milhavet L, Djiane A. Sci Rep. 2021 Mar 11;11(1):5752. doi: 10.1038/s41598-021-85056-1. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.